MedTrace Logo

Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

NCT05203380 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2023-09-08

No results posted yet for this study

Summary

Primary Objective: Part A

* To quantify deficits in cognitive functioning in adolescents with moderate-to-severe AD, using the Conners' Continuous Performance Test 3rd Edition (CPT-3) d' T-score
* To determine the entry criterion (CPT-3 d' score) for Part B

Primary Objective: Part B

* To measure changes in cognitive functioning in adolescents with moderate-to-severe AD treated with dupilumab

Secondary Objectives

* To evaluate the relationship of cognitive and sensory functioning with severity of AD in adolescent AD patients
* To evaluate the relationship between changes in AD severity and changes in cognitive and sensory functioning scores following treatment with dupilumab (Part B only).

Conditions

Interventions

DRUG

dupilumab

Weight based dosing for 16 weeks in accordance of United States prescribing information (USPI)

Sponsors & Collaborators

Principal Investigators

  • Clinical Trial Management · Regeneron Pharmaceuticals

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-27
Primary Completion
2023-03-10
Completion
2023-03-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05203380 on ClinicalTrials.gov